Mast launch ground breaking c difficile test
MAST has launched the new GenoType CDiff test from Hain Lifescience.
GenoType CDiff permits the detection and differentiation of non-pathogenic, virulent and hypervirulent (including ribotype 027) strains of Clostridium difficile directly from stool and rectal swabs, or from culture.
It is important to be able to differentiate patients who have non-pathogenic strains of C.difficile from those with virulent or hyper-virulent strains as early as possible. With this information, clinicians and infection control practitioners are able to take measures to treat appropriately, implement isolation procedures, identify outbreaks and also spot emerging strains.For further information on the Hain Lifescience GenoType CDiff, please click here.
Current laboratory methods for testing C.difficile are either time consuming (cytotoxicity or toxigenic culture), offer poor sensitivity (EIA) or are expensive (PCR). Additional to this, all of these methods offer limited information about different strains without further work needing to be performed.
The Hain Lifescience GenoType CDiff offers hospitals a same day, simple to use, proven platform that can differentiate between non-pathogenic, virulent and hypervirulent (including ribotype 027) strains. As well as having in built controls the assay also has markers for:
NOTE: This item is from our 'historic' database and may contain information which is not up to date.
Source : Mast Group Ltd. View archived contact details
Posted on July 28, 2010